



October 9, 2015

Milton Estes, MD  
San Francisco Department of Public Health Jail Health Services  
798 Brannan Street  
San Francisco, CA 94103

Dear Dr. Estes,

I'm pleased to inform you that Gilead Sciences, Inc. has approved your investigator-sponsored research proposal titled, "Curing HCV in Incarcerated Patients (CHIP)." This study (IN-US-337-1941) was approved for the provision of LDV/SOF and financial support of \$517,119.17 USD. The anticipated number of subjects to be included is 100.

Timelines for this study are as follows:

- Award date: July 31, 2015
- Project start-up date (planning and preparation): October 1, 2015
- Pilot implementation date: January 1, 2016
- Pilot end date: December 31, 2016
- Project close-out date (data analysis): March 31, 2017

Congratulations on the approval. We appreciate your interest in the Gilead Hepatitis C Phase 4 program and look forward to a successful collaboration with you on this important study

Sincerely,

Lorenzo Rossaro, MD  
Sr. Director, Medical Affairs  
Gilead Sciences  
333 Lakeside Drive  
Foster City, CA 94404  
(650) 358-3691 (phone)  
Lorenzo.rossaro@gilead.com

cc: Annie Son, Clinical Operations, Gilead Sciences  
Hadley Le, Manager, Medical Affairs, Gilead Sciences  
Amanda Copans, Associate Director, Medical Affairs, Gilead Sciences

## **Mojica, Richelle-Lynn (DPH)**

---

**From:** Yoshida, Maya (DPH)  
**Sent:** Tuesday, October 20, 2015 3:33 PM  
**To:** Mojica, Richelle-Lynn (DPH)  
**Cc:** Monico Klein, Kate (DPH); Huang, Cynthia (DPH)  
**Subject:** CHIP Payment Schedule request

Below is Gilead's proposed payment schedule for the CHIP project to add to the Accept and Expend submission. Please let me know if I need to provide the documentation below in a Word document.

Maya Yoshida-Cervantes, MPH  
Project Coordinator  
Curing HCV in Incarcerated Patients (CHIP)  
HIV & Integrated Services  
Jail Health Services, SFDPH  
415-581-3122  
maya.yoshida@sfdph.org

---

**From:** Annie Son (Contractor) <Annie.Son@gilead.com>  
**Sent:** Tuesday, October 20, 2015 3:29 PM  
**To:** Yoshida, Maya (DPH)  
**Subject:** RE: CHIP request

Dear Maya,

Below please find a proposed payment schedule for Dr. Estes' study IN-US-337-1941. Please note that there may be some slight adjustments during negotiations and this draft is intended for the purpose described in your email below. If there is further information I can provide, please let me know and I will happily send it your way. Thank you very much!

<b>Milestone Payment Schedule</b>	
(i) Upon execution of this Agreement, receipt of the final Protocol, Informed Consent Form and IRB/EC approval;	<b>\$128,279.81</b>
(ii) Upon notification of enrollment of 25 Study subjects;	<b>\$83,381.87</b>
(iii) Upon notification of enrollment of 50 Study subjects;	<b>\$83,381.87</b>
(iv) Upon notification of enrollment of 75 Study subjects;	<b>\$83,381.87</b>
(v) Upon notification of enrollment of 100 Study subjects;	<b>\$83,381.87</b>
(vi) Upon delivery to Gilead of (A) a copy of the abstract for interim data analysis as described in the Study publication plan and all supporting data; or (B) if the Study is earlier terminated, a summary of Study findings up to termination and all supporting data;	<b>\$17,103.96</b>

(vii) Upon notification to Gilead of acceptance of an abstract for presentation and approval by Gilead of Investigator's proposed travel plan to AASLD 2016 or an equivalent conference approved by Gilead. Travel costs must be limited to reasonable travel (economy class airfare, rail), accommodations, ground transportation, and meals, in accordance with industry standards;	\$2,000.00
(viii) Upon delivery to Gilead of (A) a copy of the abstract for final data analysis as described in the Study publication plan and all supporting data; or (B) if the Study is earlier terminated, a summary of Study findings up to termination and all supporting data;	\$17,103.96
(ix) Upon notification to Gilead of acceptance of an abstract for presentation and approval by Gilead of Investigator's proposed travel plan to CROI 2017 or an equivalent conference approved by Gilead. Travel costs must be limited to reasonable travel (economy class airfare, rail), accommodations, ground transportation, and meals, in accordance with industry standards;	\$2,000.00
(x) Upon delivery to Gilead of (A) a copy of the manuscript for final data analysis as described in the Study publication plan and all supporting data; or (B) if there is no acceptance of such Publication submitted, a copy of the manuscript submitted for publication and all supporting data; or (C) if the Study is earlier terminated, a summary of Study findings up to termination and all supporting data;	\$17,103.96
Total	\$517,119.17

Sincerely,

Annie Son, CCRP  
Clinical Trial Management Associate  
Gilead Sciences, Inc.  
333 Lakeside Drive, Building 300  
Foster City, CA 94404  
650-378-2175 (office)  
650-524-9531 (fax)  
[annie.son@gilead.com](mailto:annie.son@gilead.com)

---

**From:** Yoshida, Maya (DPH) [mailto:maya.yoshida@sfdph.org]  
**Sent:** Tuesday, October 20, 2015 1:44 PM  
**To:** Annie Son (Contractor)  
**Cc:** Monico Klein, Kate (DPH); Estes, Milton (DPH); Luetkemeyer, Annie (UCSF); Chyorny, Alexander  
**Subject:** CHIP request

Hi Annie,

We received notice from the Grants Manager at SFDPH and the City Controller's office that we need to provide documentation of the suggested payment schedule you originally provided in the draft contract. We do not need specific dates, just the attached page you included in 'Exhibit B: Budget and Payment Schedule.'

If this request is possible, please email it to me as soon as possible, so we can proceed with the submission request to the city. Please contact me if you have any questions or concerns. Thank you.

Maya Yoshida-Cervantes, MPH  
Project Coordinator  
Curing HCV in Incarcerated Patients (CHIP)  
HIV & Integrated Services  
Jail Health Services, SFDPH  
415-581-3122  
[maya.yoshida@sfdph.org](mailto:maya.yoshida@sfdph.org)